Chronic Urticaria Or Hives – Pipeline Review, H2 2011
Chronic Urticaria Or Hives - Pipeline Review, H2 2011
Reference Code: GMDHC1241IDB
Publication Date: August 2011
Chronic Urticaria Or Hives – Pipeline Review, H2 2011 GMDHC1241IDB / Pub August 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied
Page(1)
Chronic Urticaria Or Hives – Pipeline Review, H2 2011
Ta b le o f Co n te n ts
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Chronic Urticaria Or Hives Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Chronic Urticaria Or Hives 8
Chronic Urticaria Or Hives Therapeutics under Development by Companies 10
Chronic Urticaria Or Hives Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 12
Comparative Analysis 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Chronic Urticaria Or Hives Therapeutics - Products under Development by Companies 15
Chronic Urticaria Or Hives Therapeutics - Products under Investigation by Universities/Institutes 16
Companies Involved in Chronic Urticaria Or Hives Therapeutics Development 17
F. Hoffmann-La Roche Ltd. 17
Biofrontera AG 17
Sun Pharmaceutical Industries Limited 18
FAES Farma SA 18
JADO Technologies GmbH. 19
Chronic Urticaria Or Hives - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Combination Products 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
BF-derm1 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Bilastine - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Omalizumab - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Omeprazole + Amoxicillin + Metronidazole - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Orencia - Drug Profile 31
Chronic Urticaria Or Hives – Pipeline Review, H2 2011 GMDHC1241IDB / Pub August 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(2)
Chronic Urticaria Or Hives – Pipeline Review, H2 2011
Product Description 31
Mechanism of Action 31
R&D Progress 31
Miltefosine - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Methotrexate - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Mesalazine - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
SUN 1334 H - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
SUN 1334 H - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Xolair - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Chronic Urticaria Or Hives Therapeutics – Drug Profile Updates 39
Chronic Urticaria Or Hives Therapeutics - Discontinued Products 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 42
Contact Us 42
Disclaimer 42
Chronic Urticaria Or Hives – Pipeline Review, H2 2011 GMDHC1241IDB / Pub August 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied Page(3)
Chronic Urticaria Or Hives – Pipeline Review, H2 2011
Lis t o f Ta b le s
Number of Products Under Development for Chronic Urticaria Or Hives, H2 2011 8
Products under Development for Chronic Urticaria Or Hives – Comparative Analysis, H2 2011 9
Number of Products under Development by Companies, H2 2011 10
Number of Products under Investigation by Universities/Institutes, H2 2011 11
Comparative Analysis by Late Stage Development, H2 2011 12
Comparative Analysis by Mid Clinical Stage Development, H2 2011 13
Comparative Analysis by Early Clinical Stage Development, H2 2011 14
Products under Development by